

Immunogenicity Testing of Large Molecules & the Challenges of Developing ADA Assays

Kabir Hussain
Associate Scientist 1
MedImmune

Rise of the Large Molecules
European Bioanalysis Forum - Young Scientist Symposium

November 2015

Content

Introduction Bioanalytical Sciences, MedImmune

Immunogenicity – What? Why? How?

Differences Between PK and ADA assays

ADA Assay Parameters and Method Development Challenges

Summary




Immunogenicity

- When the patient produces antibodies to the drug – Anti-Drug Antibodies (ADA)
- Assessing the immunogenic potential of drugs is critical to ensuring safety of the patient - can be related to adverse effects
- Large molecules by nature are more prone to eliciting an immune response
- ADA can have varying impacts, in particular to PK/PD
- Multi-factorial – Product? Patient?
- Regulatory requirement



Immunogenicity testing is a mandatory requirement at various stages in the drug development process




- Immunogenicity assays are a key aspect in driving biologics through the drug development pipeline
- Preclinical GLP Toxicology studies require immunogenicity assessment
- Further immunoassays are required for clinical development




ADA assays are fundamentally different to PK assays

PK	ADA
Single assay	Multi tiered
Quantitative - utilises a standard curve	Not quantitative - uses a cut point
Defined reference standard - the drug	Uses a surrogate positive control
Potential interference from matrix substances	Potential Interference from matrix substances <u>and circulating drug</u>
Capture/detection reagents often commercially sourced	Drug molecule is labelled for use as capture and detection reagents



MSD Bridging Assay is commonly used in Immunogenicity Assessment




- Potential for better sensitivity
- Homogenous solution phase incubation simplifies assay
- Potential for shorter assay times
- Not species-specific
- Generally better drug tolerance than ELISA



Selection of a Positive Control (PC) is the first critical step in developing and ADA assay

- Ideally the PC should reflect the anticipated immune response although it is impossible to obtain a PC that is truly reflective of in-vivo ADA responses
- Options include:
 - Hyper immunisation of animal
 - Serum from patient population
 - IgG antibodies generated against the drug through hybridoma
- Need to test the selected PC for sensitivity, specificity and reproducibility



Screening and confirmatory Cut Points provide thresholds for determining and confirming positive/negative status of samples

- Screening cut point should be determined from negative control samples (i.e. from subjects not exposed to product)



Development



Validation

- Statistically determined with appropriate false positive rates (pre-clinical 1%, clinical 5%)
- Confirmatory cut point is determined by measuring inhibition of signal when samples are incubated in presence of drug
- May need to also establish SCP and CCP in patient population



Summary

- Immunogenicity assessment is vital to understanding the immunogenic potential of drugs and hence the impact on patient safety
- A tiered approach is used to initially screen samples for positive ADA response, followed by confirmation and characterisation of the response
- The assay is only as good as its positive control
- Drug tolerance assessment helps us understand the limit of our assay and whether we need to improve it
- Labelling of reagents is a critical step in assay development and needs to be tailored to the properties of the molecule



Acknowledgements

- MedImmune, Bioanalytical Sciences
 - Jo Goodman
 - Sufyan Maqbool
 - Nicholas White
- Meso Scale Discover
 - Curtis Nicholson
 - Yvonne Clements

